Toward gene therapy for disorders of globin synthesis

Seminars in Hematology

Volumn 38, Issue 4, 2001, Pages 382-392

  Tisdale, John ^a   Sadelain, Michel ^a,b  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GLOBIN; ERYTHROPOIETIN; ESTROGEN RECEPTOR; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; VIRUS VECTOR;

GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOGLOBINOPATHY; HUMAN; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REGULATOR GENE; RETROVIRUS; REVIEW; SICKLE CELL ANEMIA; THALASSEMIA; TRANSGENIC MOUSE;

EID: 0034783710     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0037-1963(01)90033-2     Document Type: Article

References (120)

1. Persistence of mixed chimerism in patients transplanted for the treatment of thalassemia
2. Two 3′ sequences direct adult erythroid-specific expression of human beta-globin genes in transgenic mice
3. A majority of mice show long-term expression of a human beta-globin gene after retrovirus transfer into hematopoietic stem cells
4. Bone marrow transplantation (BMT) in 14 children with severe sickle cell disease (SCD): The French experience. GEGMO
5. Marrow protection
6. Development of gene therapy for immunodeficiency: Adenosine deaminase deficiency
7. Cytokine prestimulation as a gene therapy strategy: Implications for using the MDR 1 gene as a dominant selectable marker
8. The beta-globin dominant control region activates homologous and heterologous promoters in a tissue-specific manner
9. Combination of interleukins 3 and 6 preserves stem cell function in culture and enhances retrovirus-mediated gene transfer into hematopoietic stem cells
10. Survival and retrovirus infection of murine hematopoietic stem cells in vitro: Effects of 5-FU and method of infection
11. + bone marrow cells
12. Gene therapy in peripheral blood lymphocytes and bone marrow for ADA-immunodeficient patients
13. Special proliferative sites are not needed for seeding and proliferation of transfused bone marrow cells in normal syngeneic mice
14. Gene marking to determine whether autologous marrow infusion restores long-term haemopoiesis in cancer patients
15. Development of lentiviral vectors for gene therapy for human diseases
16. Genetically marking human cells - Results of the first clinical gene transfer studies
17. Altering the genome by homologous recombination
18. Retroviral-mediated gene transfer into CD34-enriched human peripheral blood stem cells
19. Multiple elements in human beta-globin locus control region 5′ HS 2 are involved in enhancer activity and position-independent, transgene expression
20. Human beta-globin locus control region: Analysis of the 5′ DNase I hypersensitive site HS 2 in transgenic mice
21. Gene therapy of human severe combined immunodeficiency (SCID)-X 1 disease
22. Definition of the minimal requirements within the human beta-globin gene and the dominant control region for high level expression
23. Initial sequencing and analysis of the human genome
24. High levels of human glucocerebrosidase activity in macrophages of long-term reconstituted mice after retroviral infection of hematopoietic stem cells
25. + bone marrow progenitor cells
26. Human beta-globin gene expression in transgenic mice is enhanced by a distant DNase I hypersensitive site
27. Hematopoietic stem cells need two signals to prevent apoptosis; BCL-2 can provide one of these, Kit1/c-Kit signaling the other
28. Helper virus induced T cell lymphoma in nonhuman primates after retroviral mediated gene transfer
29. Retrovirally marked CD34-enriched peripheral blood and bone marrow cells contribute to long-term engraftment after autologous transplantation
30. Gene marking and gene therapy directed at primary hematopoietic cells
31. Lineage-specific expression of a human beta-globin gene in murine bone marrow transplant recipients reconstituted with retrovirus-transduced stem cells
32. A dominant chromatin-opening activity in 5′ hypersensitive site 3 of the human beta-globin locus control region
33. + cells for six hours without growth factors or on autologous stroma does not improve marking efficiency assessed in vivo
34. Developmental regulation of human beta-globin gene transcription: A switch of loyalties?
35. Chromatin as an essential part of the transcriptional mechanism
36. Evidence for a locus activation region: The formation of developmentally stable hypersensitive sites in globin-expressing hybrids
37. The use of granulocyte colony-stimulating factor during retroviral transduction on fibronectin fragment CH-296 enhances gene transfer into hematopoietic repopulating cells in dogs
38. Transcriptional targeting of retroviral vectors to the erythroblastic progeny of transduced hematopoietic stem cells
39. Position-independent, high-level expression of the human beta-globin gene in transgenic mice
40. Analysis of chimerism by PCR using mutant-specific primers and sequencing of B-gene region after allogenic bone marrow transplantation in sickle cell anemia
41. Serial transplantation shows that early hematopoietic precursor cells are transduced by MDR-1 retroviral vector in a mouse gene therapy model
42. In vivo expansion of gene-modified hematopoietic cells by the selective amplifier gene in a nonhuman primate model
43. Colocalization of retrovirus and target cells on specific fibronectin fragments increases genetic transduction of mammalian cells
44. Introduction of a xenogeneic gene via hematopoietic stem cell leads to specific tolerance in a Rhesus monkey model
45. High-efficiency gene transfer to human hematopoietic cells maintained in long-term marrow culture
46. Retroviral gene transfer to primitive normal and leukemic hematopoietic cells using clinically applicable procedures
47. Retroviral marking and transplantation of rhesus hematopoietic cells by non-myeloablative conditioning
48. A specific chemical difference between the globins of normal human and sickle cell anaemia hemoglobin
49. Development of a novel selective amplifier gene for controllable expansion of transduced hematopoietic cells
50. Stimulating cell proliferation through the pharmacologic activation of c-kit
51. Preselection of retrovirally transduced bone marrow avoids subsequent stem cell gene silencing and age-dependent extinction of expression of human beta-globin in engrafted mice
52. In vivo persistence of genetically-modified murine hematopoietic progenitors is not limited by the expression of the neo or GFP gene after full or minimal myeloablation
53. Persistent low level marking following non-myeloablative transplantation of rhesus PBSCS transduced with a retroviral vector carrying the Fanconi Anemia C gene
54. Expression of the human beta-globin gene following retroviral-mediated transfer into multipotential hematopoietic progenitors of mice
55. Highly efficient gene transfer into cord blood nonobese diabetic/severe combined immunodeficiency repopulating cells by oncoretroviral vector particles pseudotyped with the feline endogenous retrovirus (RD114) envelope protein
56. Improved gene transfer into baboon marrow repopulating cells using recombinant human fibronectin fragment CH-296 in combination with interleukin-6, stem cell factor, FLT-3 ligand, and megakaryocyte growth and development factor
57. Gene transfer into marrow repopulating cells: Comparison between amphotropic and gibbon ape leukemia virus pseudotyped retroviral vectors in a competitive repopulation assay in baboons
58. Many multipotential gene-marked progenitor or stem cell clones contribute to hematopoiesis in nonhuman primates
59. Hematopoietic stem cells with controllable tEpoR transgenes have a competitive advantage in bone marrow transplantation
60. + cells in ADA-deficient SC1D neonates
61. The human beta-globin gene contains a downstream developmental specific enhancer
62. Gene repair using chimeric RNA/DNA oligonucleotides
63. Locus control regions: Coming of age at a decade plus
64. Dissection of the enhancer activity of beta-globin 5′ DNase I-hypersensitive site 2 in transgenic mice
65. Engraftment of hematopoietic progenitor cells transduced with the Fanconi anemia group C gene (FANCC)
66. The abnormal hemoglobins: General principles
67. Stem cell factor, interleukin-3, and interleukin-6 promote retroviral-mediated gene transfer into murine hematopoietic stem cells
68. Enhanced host defense after gene transfer in the murine p47phox-deficient model of chronic granulomatous disease
69. Enhanced engraftment of hematopoietic progenitor cells in mice treated with granulocyte colony-stimulating factor before low-dose irradiation: Implications for gene therapy
70. Therapeutic haemoglobin synthesis in beta-thalassaemic mice expressing lentivirus-encoded human beta-globin
71. Long-term correction of beta-thalassemia intermedia in bone marrow chimeras expressing lentivirus-encoded human beta-globin
72. Fate of chromosome-marked mouse bone marrow cells tranfused into normal syngeneic recipients
73. Design of retrovirus vectors for transfer and expression of the human beta-globin gene
74. Stromal support enhances cell-free retroviral vector transduction of human bone marrow long-term culture-initiating cells
75. Bone marrow extracellular matrix molecules improve gene transfer into human hematopoietic cells via retroviral vectors
76. Mixed chimerism in thalassemic patients after bone marrow transplantation
77. Tandem AP-1-binding sites within the human beta-globin dominant control region function as an inducible enhancer in erythroid cells
78. Transduction of pluripotent human hematopoietic stem cells demonstrated by clonal analysis after engraftment in immune-deficient mice
79. Comparison of the effects of growth factors on retroviral vector-mediated gene transfer and the proliferative status of human hematopoietic progenitor cells
80. The level of mRNA encoding the amphotropic retrovirus receptor in mouse and human hematopoietic stem cells is low and correlates with the efficiency of retrovirus transduction
81. Sickle cell anemia, a molecular disease
82. Gene therapy for the hemoglobin disorders: Past, present, and future
83. Murine marrow cells expanded in culture with IL-3, 1L-6, 1L-11, and SCF acquire an engraftment defect in normal hosts
84. The minimal requirements for activity in transgenic mice of hypersensitive site 3 of the beta globin locus control region
85. The beta-globin dominant control region: Hypersensitive site 2
86. Rapamycin induces long term bone marrow chimerism in the absence of long term immunosuppression in mismatched stem cell transplantation: Application to sickle cell mice
87. Hypersensitive site 4 of the human beta globin locus control region
88. Long-term transfer and expression of the human beta-globin gene in a mouse transplant model
89. One-day ex vivo culture allows effective gene transfer into human nonobese diabetic/severe combined immune-deficient repopulating cells using high-titer vesicular stomatitis virus G protein pseudotyped retrovirus
90. Genetic treatment of severe hemoglobinopathies: The combat against transgene variegation and transgene silencing
91. Effects of retroviral vector design on expression of human adenosine deaminase in murine bone marrow transplant recipients engrafted with genetically modified cells
92. Efficient and durable gene marking of hematopoietic progenitor cells in nonhuman primates after nonablative conditioning
93. High-level erythroid expression of human alpha-globin genes in transgenic mice
94. Long-term expression of gamma-globin mRNA in mouse erythrocytes from retrovirus vectors containing the human gamma-globin gene fused to the ankyrin-1 promoter
95. A minimal ankyrin promoter linked to a human gamma-globin gene demonstrates erythroid specific copy number dependent expression with minimal position or enhancer dependence in transgenic mice
96. Critical issues in the genetic treatment of the hemoglobinopathies
97. Issues in the manufacture and transplantation of genetically modified hematopoietic stem cells
98. Basic principles of gene transfer in hematopoietic stem cells
99. The advent of lentiviral vectors: Prospects for cancer therapy
100. Generation of a high-titer retroviral vector capable of expressing high levels of the human beta-globin gene
101. LAM-PCR: Monitoring the clonal composition of the hematopoietic system in transplantation models in vivo
102. Genetically-marked rhesus peripheral blood progenitor cells (PBPC) ex vivo expanded in the presence of fibronectin 296 contribute to both short and long term engraftment
103. Humoral immune response limits gene therapy in canine MPS I
104. Selection of drugresistant bone marrow cells in vivo after retroviral transfer of human MDR 1
105. Engraftment of gene-marked hematopoietic progenitors in myeloma patients after transplant of autologous long-term marrow cultures
106. Immune response to green fluorescent protein: Implications for gene therapy
107. The 5′HS2 of the globin locus control region enhances transcription through the interaction of a multimeric complex binding at two functionally distinct NF-E 2 binding sites
108. Detailed analysis of the site 3 region of the human beta-globin dominant control region
109. Lentivirus replication and regulation
110. Recombinant DNA technique and sickle cell anemia research
111. Enhanced in vivo regenerative potential of HOXB4-transduced hematopoietic stem cells with regulation of their pool size
112. Gene therapy for hematologic disorders, HIV infection, and cancer
113. Ex vivo expansion of genetically marked rhesus peripheral blood progenitor cells results in diminished long-term repopulating ability
114. A 3′ enhancer contributes to the stage-specific expression of the human beta-globin gene
115. The "beta-like-globin" gene domain in human erythroid cells
116. Gene transfer into hematopoietic stem cells of nonhuman primates
117. Characterization of replication-competent retroviruses from nonhuman primates with virus-induced T-cell lymphomas and observations regarding the mechanism of oncogenesis
118. Introduction of new genetic material into pluripotent haematopoietic stem cells of the mouse
119. + progenitors using clinically feasible methods
120. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo